Log in

Relevant bibliographies by topics / Antineoplastic Dexamethasone Dexamethasone Antineoplastic agents / Journal articles

To see the other types of publications on this topic, follow the link: Antineoplastic Dexamethasone Dexamethasone Antineoplastic agents.

Journal articles on the topic 'Antineoplastic Dexamethasone Dexamethasone Antineoplastic agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 46 journal articles for your research on the topic 'Antineoplastic Dexamethasone Dexamethasone Antineoplastic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Erin, K. Morrison, J. Aubrey Waddell, and A. Solimando Dominic. "Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Regimen for Multiple Myeloma." Hospital Pharmacy 46, no. 11 (2011): 839–47. http://dx.doi.org/10.1310/hpj4611-839.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

2

Punke, Alexandra P., J. Aubrey Waddell, and Dominic A. Solimando. "Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma." Hospital Pharmacy 52, no. 1 (2017): 27–32. http://dx.doi.org/10.1310/hpj5201-27.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

3

Gattis, Wendy A., and D. Byron May. "Possible Interaction Involving Phenytoin, Dexamethasone, and Antineoplastic Agents: A Case Report and Review." Annals of Pharmacotherapy 30, no. 5 (1996): 520–26. http://dx.doi.org/10.1177/106002809603000516.

Full text

Abstract:

OBJECTIVE: TO describe a patient with subtherapeutic phenytoin concentrations and to review the literature regarding a possible interaction between phenytoin and chemotherapeutic agents as well as dexamethasone. CASE SUMMARY: A 29-year-old white man with brain metastases secondary to malignant melanoma consistently had suboptimal phenytoin concentrations while receiving chemotherapy consisting of cisplatin, carmustine, dacarbazine, and tamoxifen. In addition, this patient received dexamethasone, which may have influenced his phenytoin concentrations. DATA SOURCES AND STUDY SELECTION: Case repo

APA, Harvard, Vancouver, ISO, and other styles

4

Hesketh, Paul J., Mark G. Kris, Ethan Basch, et al. "Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update." Journal of Clinical Oncology 35, no. 28 (2017): 3240–61. http://dx.doi.org/10.1200/jco.2017.74.4789.

Full text

Abstract:

Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature for the period of November 2009 to June 2016. Results Forty-one publications were included in this systematic review. A phase III randomized controlled trial demonstrated that adding olanzapine to antiemetic prophylaxis reduces the likelihood of nausea among adult patients who are treated with high emetic risk antineoplastic agents. Randomized controlled trials also support an expanded role for neurokinin 1 receptor antagonists in p

APA, Harvard, Vancouver, ISO, and other styles

5

Narang, Vishal S., Charles Fraga, Narendra Kumar, et al. "Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier." American Journal of Physiology-Cell Physiology 295, no. 2 (2008): C440—C450. http://dx.doi.org/10.1152/ajpcell.00491.2007.

Full text

Abstract:

Brain edema is an important factor leading to morbidity and mortality associated with primary brain tumors. Dexamethasone, a synthetic glucocorticoid, is routinely prescribed with antineoplastic agents to alleviate pain associated with chemotherapy and reduce intracranial pressure. We investigated whether dexamethasone treatment increased the expression and activity of multidrug resistance (MDR) transporters at the blood-brain barrier. Treatment of primary rat brain microvascular endothelial cells with submicromolar concentrations of dexamethasone induced significantly higher levels of drug ef

APA, Harvard, Vancouver, ISO, and other styles

6

Gandhi, Anita K., Jian Kang, Lori Capone, et al. "Antiproliferative Effects of Lenalidomide in Combination with Chemotherapeutic Agents in Lymphoma Cell Lines." Blood 112, no. 11 (2008): 4990. http://dx.doi.org/10.1182/blood.v112.11.4990.4990.

Full text

Abstract:

Abstract Introduction: Lenalidomide (Revlimid®) is approved for the treatment of patients with myelodysplastic syndromes with a del(5q), and in combination with dexamethasone for previously treated multiple myeloma. It is currently being evaluated in lymphomas, as monotherapy or combination therapy. This study aims to identify beneficial combinations of lenalidomide with established or potential chemotherapeutic agents for lymphoma therapy. Methods: Lenalidomide-sensitive lymphoma cell lines were selected for in vitro tumor cell proliferation studies. These included mantle cell lymphoma (MCL)

APA, Harvard, Vancouver, ISO, and other styles

7

Bisping, Guido, Doris Wenning, Martin H. Kropff, et al. "Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups." Blood 106, no. 11 (2005): 112. http://dx.doi.org/10.1182/blood.v106.11.112.112.

Full text

Abstract:

Abstract Novel antineoplastic agents have opened perspectives to more selective treatment of multiple myeloma (MM). Targets include FGFR3 or c-maf and VEGFR1 expressed in MM subgroups carrying t(4;14)(p16.4;q32) or t(14;16)(q32;q23), respectively. The t(4;14) MM subgroup, overexpressing FGFR3, has been recently demonstrated to be sensitive to induction of apoptosis by receptor tyrosine kinase (RTK) inhibitors [Bisping, Blood102, 661, 2003; Podar, Blood103, 3474, 2004; Trudel, Blood105, 2941, 2005]. The present study aimed at investigating mechanisms of enhanced anti-myeloma effects of BIBF 100

APA, Harvard, Vancouver, ISO, and other styles

8

Hamasaki, Makoto, Teru Hideshima, Kenji Ishitsuka, et al. "SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma." Blood 104, no. 11 (2004): 3466. http://dx.doi.org/10.1182/blood.v104.11.3466.3466.

Full text

Abstract:

Abstract SDX-101 is an oral antineoplastic agent, has been evaluated in a phase I/II study in B-cell malignancies. It induces cytotoxicity at least in part, by significantly inhibiting expression of Mcl-1, an anti-apoptotic Bcl-2 family protein which is highly expressed in CLL cells. Here, we examined the cytotoxicity of SDX-101 against multiple myeloma (MM) cell lines. SDX-101 significantly inhibited growth in MM.1S, U266, RPMI8226 MM cell lines using MTT assays in a time- and dose-dependent fashion, with IC50s of 0.6mM, 1.0mM, and 0.4mM, respectively. In contrast, SDX-101 did not induce cyto

APA, Harvard, Vancouver, ISO, and other styles

9

Carroll, Michael P., Olin Feuerbacher, Andrew M. Yeager та Terry H. Landowski. "Bortezomib Induces Rapid Upregulation of Topoisomerase IIα and Demonstrates Schedule-Dependent Synergistic Cytotoxicity with Anthracyclines and Etoposide in Acute Myeloid Leukemia and Myeloma Cell Lines." Blood 106, № 11 (2005): 2478. http://dx.doi.org/10.1182/blood.v106.11.2478.2478.

Full text

Abstract:

Abstract The proteasome inhibitor bortezomib (BZ) has significant antineoplastic activity in multiple myeloma, lymphoma and acute leukemia. Recently, it has been shown that BZ can potentiate the activity of other antitumor agents in vitro. Topoisomerase IIα (topo IIα) is known to be regulated by proteasomal degradation, suggesting that proteasomal inhibition might increase intracellular topo IIα levels and thereby enhance sensitivity to topo IIα-targeted agents, including etoposide, daunorubicin and mitoxantrone. Incubation with sublethal concentrations of BZ led to rapid upregulation of topo

APA, Harvard, Vancouver, ISO, and other styles

10

Gribben, John G., Nathan Fowler, and Franck Morschhauser. "Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma." Journal of Clinical Oncology 33, no. 25 (2015): 2803–11. http://dx.doi.org/10.1200/jco.2014.59.5363.

Full text

Abstract:

Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated through multiple types of immune cells found in the tumor microenvironment, including B, T, natural killer (NK), and dendritic cells. Recently, the E3 ubiquitin ligase cereblon was identified as a molecular target that may underlie the effects of lenalidomide on tumor cells, as well as on cells in the tumor microenvironment. Decreases in cereblon attenuate these effects and also confer resistance to lenalidomide. Tumoricidal effects of lenalidomide are associated with re

APA, Harvard, Vancouver, ISO, and other styles

11

Hainsworth, J., W. Harvey, K. Pendergrass, et al. "A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy." Journal of Clinical Oncology 9, no. 5 (1991): 721–28. http://dx.doi.org/10.1200/jco.1991.9.5.721.

Full text

Abstract:

Ondansetron (GR 38032F), a selective antagonist of serotonin subtype 3 receptors, is effective in the prevention of emesis associated with cisplatin as well as other chemotherapeutic agents. In this randomized, single-blind, multicenter, parallel group study, we compared the efficacy and safety of intravenous (IV) ondansetron with IV metoclopramide in the prevention of nausea and vomiting associated with high-dose (greater than or equal to 100 mg/m2) cisplatin chemotherapy. Three hundred seven patients receiving their first dose of cisplatin, either alone or in combination with other antineopl

APA, Harvard, Vancouver, ISO, and other styles

12

Miyashita, T., and JC Reed. "Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line." Blood 81, no. 1 (1993): 151–57. http://dx.doi.org/10.1182/blood.v81.1.151.151.

Full text

Abstract:

Abstract Previous studies have shown that the bcl-2 gene encodes a mitochondrial protein that contributes to neoplastic cell expansion primarily by promoting cell survival through interference with “programmed cell death” (PCD), also termed “apoptosis.” Because many chemotherapeutic drugs are capable of initiating pathways leading to apoptosis, we determined whether deregulated bcl-2 expression could render cells resistant to several drugs commonly used in the treatment of non- Hodgkin's lymphomas, including dexamethasone (DEX), methotrexate (MTX), 1-beta-D-arabinofuranosyl-cytosine (Ara-C), e

APA, Harvard, Vancouver, ISO, and other styles

13

Miyashita, T., and JC Reed. "Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line." Blood 81, no. 1 (1993): 151–57. http://dx.doi.org/10.1182/blood.v81.1.151.bloodjournal811151.

Full text

Abstract:

Previous studies have shown that the bcl-2 gene encodes a mitochondrial protein that contributes to neoplastic cell expansion primarily by promoting cell survival through interference with “programmed cell death” (PCD), also termed “apoptosis.” Because many chemotherapeutic drugs are capable of initiating pathways leading to apoptosis, we determined whether deregulated bcl-2 expression could render cells resistant to several drugs commonly used in the treatment of non- Hodgkin's lymphomas, including dexamethasone (DEX), methotrexate (MTX), 1-beta-D-arabinofuranosyl-cytosine (Ara-C), etoposide

APA, Harvard, Vancouver, ISO, and other styles

14

Aisu, Naoya, Yoichiro Yoshida, Teppei Yamada, et al. "The difference between the subjective and objective evaluation of oxaliplatin-induced vascular pain due to administer chemotherapy via peripheral vein." Journal of Clinical Oncology 33, no. 3_suppl (2015): 651. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.651.

Full text

Abstract:

651 Background: We have reported the safety and effectiveness of chemotherapy via median cubital vein for metastatic colorectal cancer without implantation of a central venous port. However, vascular pain (VP) occasionally requires switching of the drip infusion route during chemotherapy for the administration of oxaliplatin via the peripheral vein. VP and phlebitis induced by intravenous infusion of antineoplastic agents reduces the rate of completion or continuation of chemotherapy. We also reported that addition of dexamethasone to oxaliplatin drip infusion controlled the vascular pain caus

APA, Harvard, Vancouver, ISO, and other styles

15

Thomas, Deborah A., Hagop M. Kantarjian, Wendy Stock, et al. "Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)." Blood 110, no. 11 (2007): 858. http://dx.doi.org/10.1182/blood.v110.11.858.858.

Full text

Abstract:

Abstract Introduction: Vincristine sulfate (VCR) is a lipophilic, cell-cycle specific, antineoplastic agent that inhibits cell division by specifically binding to tubulin in mitotic spindles. The activity of VCR is dose and time-dependent, but central and peripheral neuropthy prohibits its use beyond doses of 1.4 mg/m2 (capped at 2 mg). Marqibo is a formulation of VCR encapsulated in a sphingomyelin/cholesterol liposome (OPTISOME) with a longer half-life than VCR. In murine models using L1210 or P388 lymphoid leukemia cell lines, Marqibo demonstrated greater anti-tumor activity compared with V

APA, Harvard, Vancouver, ISO, and other styles

16

Castro, Marielly Cunha, Suely Amorim de Araújo, Thaís Rezende Mendes, Glauciane Silva Vilarinho, and Maria Angélica Oliveira Mendonça. "Effectiveness of antiemetics in control of antineoplastic chemotherapy-induced emesis at home." Acta Paulista de Enfermagem 27, no. 5 (2014): 412–18. http://dx.doi.org/10.1590/1982-0194201400069.

Full text

Abstract:

Objective Evaluating if antiemetics are effective in the prevention or treatment at home, of chemotherapy-induced emesis. Methods In total, were included 42 women with breast cancer in moderately emetogenic chemotherapy, using dexamethasone/ondansetron before each cycle. The frequency of nausea and vomiting was obtained by applying the instrument in the pre-chemotherapy period, and 24h, 48h, 72h and 96h after chemotherapy. The use of antiemetics was considered in accordance with adherence to medical prescription. Results All patients (n = 42, 100%) reported emesis at some point. Only five case

APA, Harvard, Vancouver, ISO, and other styles

17

Anaissie, Elias J., Giampaolo Talamo, Edgardo Angtuaco, et al. "Avascular Necrosis of Bone after Therapy for Multiple Myeloma: A Study of 561 Consecutive Patients." Blood 104, no. 11 (2004): 3467. http://dx.doi.org/10.1182/blood.v104.11.3467.3467.

Full text

Abstract:

Abstract Purpose: To assess the prevalence, time of onset, risk factors, and outcome of avascular necrosis (AVN) of bone in patients with multiple myeloma undergoing antineoplastic therapy. Patients And Methods: We reviewed the medical records of 561 myeloma patients (553 evaluable) enrolled in a treatment protocol consisting of dexamethasone-containing induction chemotherapy, autologous stem cell transplantation (ASCT), consolidation chemotherapy and maintenance with alfa-interferon. Patients were randomized at enrollment to receive thalidomide (269 pts) or no thalidomide (284 pts) throughout

APA, Harvard, Vancouver, ISO, and other styles

18

Fiscella, Richard, Gholan A. Peyman, Judy Elvart, and Beatrice Yue. "In Vitro Evaluation of Cellular Inhibitory Potential of Various Antineoplastic Drugs and Dexamethasone." Ophthalmic Surgery, Lasers and Imaging Retina 16, no. 4 (1985): 247–49. http://dx.doi.org/10.3928/1542-8877-19850401-07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Coyne, Cody P., and Lakshmi Narayanan. "Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549)." Anti-Cancer Agents in Medicinal Chemistry 19, no. 6 (2019): 802–19. http://dx.doi.org/10.2174/1871520619666181204100226.

Full text

Abstract:

Background:Traditional chemotherapeutics of low-molecular weight diffuse passively across intact membrane structures of normal healthy cells found in tissues and organ systems in a non-specific unrestricted manner which largely accounts for the induction of most sequelae which restrict dosage, administration frequency, and duration of therapeutic intervention. Molecular strategies that offer enhanced levels of potency, greater efficacy and broader margins-of-safety include the discovery of alternative candidate therapeutics and development of methodologies capable of mediating properties of se

APA, Harvard, Vancouver, ISO, and other styles

20

Yokoyama, Tetsuya, Seiji Shinozaki, Hidenobu Arimura, Keita Nakatomi, and Hiroshi Wataya. "Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer." Case Reports in Oncology 10, no. 1 (2017): 239–43. http://dx.doi.org/10.1159/000463381.

Full text

Abstract:

Various adverse events can occur during antineoplastic therapy. A 67-year-old diabetic woman developed an emphysematous urinary tract infection (UTI) associated with chemoradiotherapy for lung cancer. She had received weekly carboplatin plus paclitaxel with thoracic radiotherapy and developed a fever on day 19. Computed tomography showed a large quantity of gas within the urinary tract. She was therefore diagnosed with emphysematous UTI. Poor diabetes control due to the weekly administration of dexamethasone, an existing urinary tract obstruction, and bone marrow suppression were involved in h

APA, Harvard, Vancouver, ISO, and other styles

21

Souza, Andressa B., and Benedito C. Cordeiro. "Evaluation of pre-chemotherapy antiemetic prescriptions in a hospital unit." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 10, no. 3 (2020): 341. http://dx.doi.org/10.30968/rbfhss.2019.103.0341.

Full text

Abstract:

Introduction: Antineoplastic drugs, due to their high toxicity, can lead to adverse reactions to drugs, such as emesis, which causes discomfort to the patient. These drugs can be classified according to emetogenic potential and have appropriate treatment protocols. Objectives: The aim of this study is to evaluate whether there is compliance between antiemetic prescription in patients receiving antineoplastic treatment in a hospital unit, according to pre-established emesis prevention protocols. Methods: This is a cross-sectional retrospective study of chemotherapy prescriptions analysis from J

APA, Harvard, Vancouver, ISO, and other styles

22

Sidana, Surbhi, Beth Faiman, Paul Elson, et al. "Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis." Blood 122, no. 21 (2013): 1975. http://dx.doi.org/10.1182/blood.v122.21.1975.1975.

Full text

Abstract:

Abstract Background Information is limited on the efficacy and long-term tolerability of weekly ubcutaneous (SC) bortezomib (BTZ), especially when given alone or combined only with glucocorticoids. We implemented use of SC BTZ in 12/2010 and based on equal AUC and efficacy with twice a week SC as IV BTZ (Moreau et al. Lancet Oncology 2011) at reduced but still significant neurotoxicity allowed weekly SC, maintaining the BTZ starting dose at 1.3mg/m2. Methods Multiple myeloma (MM) and AL amyloidosis (ALA) patients (pts) who had received SC BTZ by February 2013 were identified from our plasma ce

APA, Harvard, Vancouver, ISO, and other styles

23

Talamo, Giampaolo, Edgardo Angtuaco, Ronald C. Walker, et al. "Avascular Necrosis of Femoral and/or Humeral Heads in Multiple Myeloma: Results of a Prospective Study of Patients Treated With Dexamethasone-Based Regimens and High-Dose Chemotherapy." Journal of Clinical Oncology 23, no. 22 (2005): 5217–23. http://dx.doi.org/10.1200/jco.2005.11.676.

Full text

Abstract:

Purpose To assess the prevalence, time of onset, risk factors, and outcome of avascular necrosis (AVN) of bone in patients with multiple myeloma undergoing antineoplastic therapy. Patients and Methods A total of 553 consecutive assessable patients were enrolled onto a treatment protocol consisting of dexamethasone-containing induction chemotherapy, autologous stem-cell transplantation, consolidation chemotherapy, and maintenance with interferon alfa. Patients were randomly assigned to receive thalidomide (269 patients) or no thalidomide (284 patients) throughout the study period. Results With

APA, Harvard, Vancouver, ISO, and other styles

24

Coyne, C. P., and Lakshmi Narayanan. "Dexamethasone-(C₂₁-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)." Drug Design, Development and Therapy Volume 10 (August 2016): 2575–97. http://dx.doi.org/10.2147/dddt.s102075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ghosh, Nilanjan, Noah Tucker, Marianna Zahurak, Jocelyn L. Wozney, Ivan M. Borrello, and Carol Ann Huff. "Addition Of Clarithromycin To Lenalidomide and Dexamethasone (BiRd) Is Effective In Multiple Myeloma After Progression On Lenalidomide and Dexamethasone." Blood 122, no. 21 (2013): 1960. http://dx.doi.org/10.1182/blood.v122.21.1960.1960.

Full text

Abstract:

Abstract Background The combination of clarithromycin (biaxin), lenalidomide and dexamethasone (BiRd) has been previously shown by Niesvizky, R., et al as a very effective regimen in newly diagnosed myeloma (MM) with an overall response rate of 90.3% and a very good partial response (VGPR) rate of 73.6%. Long term follow up has shown a median progression free survival of 49 months. In a case control comparison, Gay, F., et al showed that BiRd has superior outcomes compared to lenalidomide and dexamethasone (Rd). Clarithromycin appears to optimize the pharmacologic effect of glucocorticoids by

APA, Harvard, Vancouver, ISO, and other styles

26

Duyvendak, Michiel, Mark Naunton, Bert J. Kingma, and Jacobus RBJ Brouwers. "Thalidomide-Associated Thrombocytopenia." Annals of Pharmacotherapy 39, no. 11 (2005): 1936–39. http://dx.doi.org/10.1345/aph.1g256.

Full text

Abstract:

OBJECTIVE To report thrombocytopenia in a patient prescribed thalidomide for multiple myeloma (MM). CASE SUMMARY A 70-year-old woman was diagnosed in 2003 with MM. At diagnosis, melphalan 0.25 mg/kg/day and prednisolone 2 mg/kg/day were started; however, the patient became refractory to therapy. Melphalan and prednisolone were discontinued, and monotherapy with dexamethasone 40 mg for 12 days per month was started. The patient's hematologic condition deteriorated again after about one year; dexamethasone was discontinued, and treatment with oral thalidomide 200 mg/day was initiated. About 2 we

APA, Harvard, Vancouver, ISO, and other styles

27

Ali, Sundas, Insija Ilyas Selene, Muhammad Tayyeb, et al. "Efficacy of Four Drug Regimens in Multiple Myeloma: A Systemic Review." Blood 136, Supplement 1 (2020): 21–22. http://dx.doi.org/10.1182/blood-2020-142008.

Full text

Abstract:

Introduction: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by neoplastic proliferation of plasma cells. Despite advances in treatment, therapeutic uncertainties persist. The addition of a fourth drug with the standard regimen gives a favorable prognosis and efficacy profile in MM. This systematic review highlights four-drug regimens' efficacy and safety for the treatment of newly diagnosed (ND) and relapsed refractory (RR) MM. Methodology: We performed a comprehensive literature search using four major databases (Pubmed, Cochrane Library, Embase, and ClinicalTrials.gov). Our

APA, Harvard, Vancouver, ISO, and other styles

28

Valero, V., F. A. Holmes, R. S. Walters, et al. "Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer." Journal of Clinical Oncology 13, no. 12 (1995): 2886–94. http://dx.doi.org/10.1200/jco.1995.13.12.2886.

Full text

Abstract:

PURPOSE To determine the efficacy (objective response rate and duration of response and survival) and toxicity of docetaxel in patients with strictly defined anthracycline-resistant metastatic breast cancer (MBC). PATIENTS AND METHODS Thirty-five patients with bidimensionally measurable MBC who had progressive disease while receiving anthracycline-containing chemotherapy were registered onto the phase II trial. Docetaxel was administered at a dose of 100 mg/m2 over 1 hour every 21 days. RESULTS Thirty-four patients were assessable for disease response; 18 (53%; 95% confidence interval [CI], 35

APA, Harvard, Vancouver, ISO, and other styles

29

França, Monique Sedlmaier, Pedro Luiz Serrano Usón Junior, Yuri Philippe Pimentel Vieira Antunes, et al. "Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy." Einstein (São Paulo) 13, no. 2 (2015): 221–25. http://dx.doi.org/10.1590/s1679-45082015ao3097.

Full text

Abstract:

ABSTRACT Objective: To assess adherence of the prescribing physicians in a private cancer care center to the American Society of Clinical Oncology guideline for antiemetic prophylaxis, in the first cycle of antineoplastic chemotherapy. Methods: A total of 139 chemotherapy regimens, of 105 patients, were evaluated retrospectively from 2011 to 2013. Results: We observed 78% of non-adherence to the guideline rate. The main disagreements with the directive were the prescription of higher doses of dexamethasone and excessive use of 5-HT3 antagonist for low risk emetogenic chemotherapy regimens. On

APA, Harvard, Vancouver, ISO, and other styles

30

Klein, Ulrike, Igor W. Blau, Monika Engelhardt, et al. "Efficacy and Tolerability of Lenalidomide/Dexamethasone in Intensively Pretreated Myeloma Patients: Experiences from the German Named Patient Program." Blood 110, no. 11 (2007): 4834. http://dx.doi.org/10.1182/blood.v110.11.4834.4834.

Full text

Abstract:

Abstract Lenalidomide (Len), an immunomodulatory drug, in combination with dexamethasone (Dex) is a new treatment option for patients (pts) with relapsed or refractory multiple myeloma (MM). Reimbursement and drug laws in Germany allow treatment before marketing authorization of a given drug, if no alternatives are available for life-threatening diseases. AIM: To evaluate efficacy and tolerability of MM pts treated with Len/Dex in the German named patient (pt) program. PATIENT AND METHODS: A comprehensive, previously tested, questionnaire was used to document data from consecutive pt series in

APA, Harvard, Vancouver, ISO, and other styles

31

Hrusovsky, Irena, Berthold Emmerich, Albert von Rohr, et al. "Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey." Blood 112, no. 11 (2008): 2775. http://dx.doi.org/10.1182/blood.v112.11.2775.2775.

Full text

Abstract:

Abstract In myeloma therapy retreatment after successful therapy is frequently considered. Here we present pooled data from a German and Swiss multicenter, retrospective survey (26866138MMY4014). The survey started in Germany and was later extended to Switzerland. German data have already been published before. Here we report on the entire cohort of patients for the first time. For inclusion into this analysis, patients with MM had to have had preceding bortezomib treatment, resulting in at least partial remission and a second therapy with Bortezomib on relapse. The intention of this trial was

APA, Harvard, Vancouver, ISO, and other styles

32

Yano, Ryoichi, Tetsuji Kurokawa, Hideaki Tsuyoshi, et al. "Transient Elevation of International Normalized Ratio During Cisplatin-Based Chemotherapy in Patients Who are Taking Warfarin." Annals of Pharmacotherapy 45, no. 10 (2011): 1308. http://dx.doi.org/10.1345/aph.1q290.

Full text

Abstract:

Objective: To report 2 cases of a probable interaction between cisplatin and warfarin. Case Summary: Two cases of transient elevation of international normalized ratio (INR) during Irinotecan (60 mg/m2 on days 1, 8, and 15) plus cisplatin (60 mg/m2 on day 1) chemotherapy with concomitant warfarin are presented. In both cases, warfarin dosages were stable at the therapeutic target range prior to initiation of chemotherapy. Granisetron hydrochloride (3 mg on days 1, 6, and 15) and dexamethasone (13.2 mg on day 1 and 6.6 mg on days 2, 3, 8, and 15) were used prior to irinotecan administration in

APA, Harvard, Vancouver, ISO, and other styles

33

Krejci, Marta, Zdenek Adam, Ludek Pour, Jana Pelcova, and Jiri Mayer. "Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities." Blood 122, no. 21 (2013): 3233. http://dx.doi.org/10.1182/blood.v122.21.3233.3233.

Full text

Abstract:

Abstract Background Lenalidomide is immunomodulatory drug with a range of antineoplastic actions, it is highly effective in multiple myeloma (MM). Lenalidomide has been associated with various adverse side effects including fatigue, constipation, haematological and neurological toxicity. Thyroid dysfunction has been reported as a possible side effect of lenalidomide with incidence 5-10%. Symptoms of thyroid dysfunction can overlap with some side effects of lenalidomide. Thyroid hormone levels are not regularly evaluated in patients (pts) on lenalidomide. Aim In this report we have analysed a c

APA, Harvard, Vancouver, ISO, and other styles

34

Puig, Noemi, Miguel T. Hernández, Laura Rosinol Dachs, et al. "Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial." Blood 134, Supplement_1 (2019): 694. http://dx.doi.org/10.1182/blood-2019-123997.

Full text

Abstract:

Continuous treatment with lenalidomide (R) and dexamethasone (d) is a standard of care for multiple myeloma (MM) patients (pts) not candidates for autologous stem cell transplantation (ASCT). As previously reported, the addition of Clarithromycin (C) to Rd has proven to be safe and effective, and case-control analyses suggested a significant additive value with the combination. C optimizes the therapeutic effect of glucocorticoids by increasing the area under the curve, has immunomodulatory effects and may have direct antineoplastic properties. However, there are not randomized phase III trial

APA, Harvard, Vancouver, ISO, and other styles

35

Nasso, Daniela, Silvia Bolis, Elisabetta Abruzzese, et al. "Antiemetic Prophylaxis with NEPA (NETUPITANT/PALONOSETRON) and Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Hodgkin'S Lymphoma Naïve Patients Receiving ABVD Regimen: A Multicenter Phase Iia Study." Blood 136, Supplement 1 (2020): 18. http://dx.doi.org/10.1182/blood-2020-139297.

Full text

Abstract:

Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when highly emetogenic antineoplastic drugs are used. Uncontrolled emesis can profoundly impact on the patient's quality of life and ability to survive, by causing dehydration, electrolyte imbalance, malnutrition and treatment discontinuation. The ABVD regimen (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) is considered the standard of care for first-line treatment of Hodgkin's Lymphoma. Among these drugs, dacarbazine and adriamycin are the most emetogenic, being classified as highly and mode

APA, Harvard, Vancouver, ISO, and other styles

36

Besse, Andrej, Lenka Besse, Sara C. Stolze, et al. "Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity." Blood 136, Supplement 1 (2020): 11. http://dx.doi.org/10.1182/blood-2020-136253.

Full text

Abstract:

INTRODUCTION Nelfinavir is a highly lipophilic, first generation HIV-protease inhibitor (HIV-PI) approved for HIV treatment. It has largely been replaced by next-generation HIV-PI with increased specificity and efficacy for HIV therapy, partly reflecting the significant rate of the off-target activity of nelfinavir. Increasing preclinical and clinical evidence shows that nelfinavir has broad anti-cancer activity as a single agent and in combination, potentially related to its off-target activity in mammalian cells. Nelfinavir is particularly effective in the treatment of proteasome inhibitor-r

APA, Harvard, Vancouver, ISO, and other styles

37

Cong, Luo, Mingge Shang, Lei Chen, et al. "A cross-sectional study on effectiveness of antiemetic regimens for chemotherapy-induced nausea and vomiting: A single-center retrospect study of 1,000 patients." Journal of Clinical Oncology 39, no. 15_suppl (2021): e24100-e24100. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e24100.

Full text

Abstract:

e24100 Background: Chemotherapy-induced nausea and vomiting (CINV) is a common symptom in patients who undergoing chemotherapy, it is very important to control CINV to maintain dose intensity and patients' quality of life. To analyse the current situation of CINV for the tumor patients who undergoing chemotherapy, we used a cross-sectional survey to assess CINV status in those patients, and whether the drugs used by doctors in each department met the guidelines, and compared the efficacy of different antiemetic regimens on acute and delayed CINV overall post-chemotherapy periods. Methods: 1,00

APA, Harvard, Vancouver, ISO, and other styles

38

Cong, Luo, Mingge Shang, Lei Chen, et al. "A cross-sectional study on the effectiveness of antiemetic regimens for chemotherapy-induced nausea and vomiting: A single center retrospect study of 1,000 patients." Journal of Clinical Oncology 39, no. 15_suppl (2021): e24055-e24055. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e24055.

Full text

Abstract:

e24055 Background: Chemotherapy-induced nausea and vomiting (CINV) is a common symptom in patients who undergoing chemotherapy, it is very important to control CINV to maintain dose intensity and patients' quality of life. To analyse the current situation of CINV for the tumor patients who undergoing chemotherapy, we used a cross-sectional survey to assess CINV status in those patients, and whether the drugs used by doctors in each department met the guidelines, and compared the efficacy of different antiemetic regimens on acute and delayed CINV overall post-chemotherapy periods. Methods: 1,00

APA, Harvard, Vancouver, ISO, and other styles

39

Demasi, Ana Paula, Marcelo Henrique Napimoga, Elizabeth Ferreira Martinez, et al. "Antimyeloma In Vitro Activity Of 15-Deoxy-D12,14-Prostaglandin J2 Is Associated With Endoplasmic Reticulum Stress In a Reactive Oxygen Species-Dependent Fashion." Blood 122, no. 21 (2013): 4913. http://dx.doi.org/10.1182/blood.v122.21.4913.4913.

Full text

Abstract:

Abstract Multiple myeloma (MM) is an incurable malignancy characterized by the accumulation of terminally differentiated plasma cells in the bone marrow, usually accompanied by continuous monoclonal immunoglobulin production. This production requires proper folding and assembly of immunoglobulin chains, conducted by disulfide bonds formation in the endoplasmic reticulum (ER). Disulfide bonds are formed via electron transfer from thiol groups in a protein relay system, from protein disulfide isomerase (PDI) to ER oxidoreductase1 (ERO1) and finally to molecular oxygen, generating one molecule of

APA, Harvard, Vancouver, ISO, and other styles

40

Shuai, Xiao, Juan Xu, Xushu Zhong, et al. "Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China." Blood 128, no. 22 (2016): 4882. http://dx.doi.org/10.1182/blood.v128.22.4882.4882.

Full text

Abstract:

Abstract Objective. Hemophagocytic lymphohistiocytosis (HLH), also known as Hemophagocytic Syndrome (HPS), is an increasingly recognized clinical syndrome that is characterized by extreme immune activation. HLH was first described as an inherited immune disorder in pediatrics, but it may also arise in adults as the result of persistent antigen stimulation due to infections, autoimmune disorders or malignancies. Early recognition of HLH and appropriate treatment are critically important. For the pediatric patients, the Histiocyte Society Study Group for HLH has developed the HLH-94 and HLH-2004

APA, Harvard, Vancouver, ISO, and other styles

41

Hus, Marek, Norbert Grzasko, Dariusz Jawniak, Marta Szostek, and Anna Dmoszynska. "Lovastatin as Salvage Immunomodulatory Therapy in Patients with Refractory and Relapsed Multipla Myeloma." Blood 106, no. 11 (2005): 1567. http://dx.doi.org/10.1182/blood.v106.11.1567.1567.

Full text

Abstract:

Abstract In the recent years the treatment of patients with multiple myeloma (MM) has changed because of the introduction of new agents, mainly thalidomide (THAL) and its derivatives and bortezomib, an inhibitor of the 20S proteasome. Lovastatin (LOV) and other inhibitors of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, have been demonstrated to exibit antineoplasmatic and proapoptotic properties in numerous in vitro studies involving myeloma cell lines including our own experiments. This observation induced us to administer LOV in combination with THAL and dexamethaso

APA, Harvard, Vancouver, ISO, and other styles

42

Niesvizky, Ruben, P. G. Richardson, P. Sonneveld, et al. "Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies." Blood 108, no. 11 (2006): 3529. http://dx.doi.org/10.1182/blood.v108.11.3529.3529.

Full text

Abstract:

Abstract BACKGROUND: The phase 2 SUMMIT trial of patients (pts) with relapsed and refractory MM showed that btz (VELCADE®) is active, with a response rate of 27% (CR/PR) as a single agent, median TTP of 7 months, and median OS of 17 months. The phase 3 APEX trial in pts with relapsed MM following 1–3 prior therapies showed btz to be superior to high-dose dexamethasone (dex) in terms of response rate, TTP, and OS. Updated APEX data show a CR/PR rate of 43%, median TTP of 6.2 months, and median OS of 29.8 months. This analysis evaluated the relationship between quality of response to btz (CR/nCR

APA, Harvard, Vancouver, ISO, and other styles

43

Falnoga, Ingrid, Darja Mazej, Helena Podgornik, Samo Zver, Peter Cernelc, and Zdenka Slejkovec. "Critical Serum-Selenium Levels in APL and MM Patients during ATO-Treatment (According to APL and MAC/DAC Schemes)." Blood 124, no. 21 (2014): 5231. http://dx.doi.org/10.1182/blood.v124.21.5231.5231.

Full text

Abstract:

Abstract Introduction Arsenic trioxide (As2O3; ATO; Trisenox®) is an antineoplastic chemotherapeutic agent used for the treatment of acute promyelocytic leukemia (APL) and experimentally also for other malignancies including multiple myeloma (MM). As the therapeutic doses are rather high, and arsenic-selenium interactions well-known (arsenic complexation by selenium with subsequent excretion by bile), we assume that arsenic interferes in the selenium (Se) metabolism during the treatment. As selenium deficiency (<40 ng Se/g) can be detrimental in many ways, the aim of our study was to follow

APA, Harvard, Vancouver, ISO, and other styles

44

Maiese, Eric M., Xinmei Zhu, Bingcao Wu, Yen-Wen Chen, and Sikander Ailawadhi. "Economic Burden of Emergency Room (ER) Visits and Hospitalizations Among Newly Diagnosed Multiple Myeloma (NDMM) Patients in the United States." Blood 134, Supplement_1 (2019): 4715. http://dx.doi.org/10.1182/blood-2019-127071.

Full text

Abstract:

Background: With the introduction of the Oncology Care Model, which aims to provide higher quality, more coordinated oncology care at the same or lower cost to Medicare, physician practices are increasingly being held accountable for performance and financial measures.1 Urgent care (emergency room [ER] visits and hospitalizations) is known to contribute a significant proportion of healthcare costs, and while there has been a focus on drug costs, little is known about the utilization or economic impact of urgent care among multiple myeloma (MM) patients. Objective: To identify the primary reaso

APA, Harvard, Vancouver, ISO, and other styles

45

Peddi, Prakash, Nisha Elizabeth Ajit, Gary Von Burton, and Hazem El-Osta. "Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam." BMJ Case Reports, December 23, 2016, bcr2016217393. http://dx.doi.org/10.1136/bcr-2016-217393.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

David, Julia, Lev Yagudayev, and Robert Galagan. "SAT-207 Adrenocortical Carcinoma in Untreated Congenital Adrenal Hyperplasia." Journal of the Endocrine Society 4, Supplement_1 (2020). http://dx.doi.org/10.1210/jendso/bvaa046.1943.

Full text

Abstract:

Abstract Background: Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of various enzymes participating in steroid hormone synthesis. It occurs in 1 in 5000 to 1 in 15000 births. The most common (90-95%) cause of CAH is the absence of the enzyme 21-hydroxylase. We are presenting a case of a 34 year old male with untreated congenital adrenal hyperplasia due 21-hydroxylase deficiency and metastatic adrenocortical carcinoma. Case: A 34 year old male with a history of classic congenital adrenal hyperplasia (CAH) untreated

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!